2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 291-292
Technology and Procedures, Omics Technologies, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Immunotherapy, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

19 Tirzepatide reversibly reprograms the inflammatory output of hematopoiesis in diet-induced obesity

Nathan M. Krah, MD, PhD, Elena Gonzalez Alvarado2, Amog P Urs, PhD3, Chinmayee Goda, PhD4, Yaphet Bustos, BS5, Spencer Gygi6, Dennis Towne7, Ashish Toshniwal, PhD8, Juan Cantres-Velez9, Corey N Cunningham, PhD10, Sankalp Arora, MD11, Ramiro Garzon, MD12, Adrienne M. Dorrance, PhD13, Jared Rutter, PhD14, Amandine Chaix, PhD15
1 University of Utah, Salt Lake City, Utah, United States
2 University of Utah, Salt Lake City, Utah, United States
3 University of Utah, Salt Lake City, United States
4 University of Utah, Salt Lake City, United States
5 University of Utah, Salt Lake City, Utah, United States
6 University of Utah, Salt Lake City, Utah, United States
7 University of Utah, Salt Lake City, United States
8 University of Utah, Salt Lake City, Utah, United States
9 University of Utah, Salt Lake City, Utah, United States
10 University of Utah, Salt Lake City, Utah, United States
11 University of Utah, Salt Lake City, United States
12 University of Utah, Salt Lake City, Utah, United States
13 University of Utah, Salt Lake City, United States
14 University of Utah, Salt Lake City, Utah, United States
15 University of Utah, Salt Lake City, Utah, United States
Background: Obesity causes chronic low-grade inflammation and expansion of circulating monocytes through myeloid-biased hematopoiesis. Tirzepatide, a dual GLP-1/GIP receptor agonist, produces substantial weight loss, but whether it reverses obesity-associated hematopoietic and innate immune states beyond the effects of caloric restriction (CR) remains unknown. We hypothesized that tirzepatide could remodel obesity-associated hematopoiesis and curb inflammatory monocyte production during weight loss.

Methods: Mice were fed ad libitum high-fat diet (HFD) for 12 weeks and then randomized to continue HFD alone, receive tirzepatide while remaining on ad libitum HFD, or undergo weight-matched HFD CR (n=6 per group). Lean ad libitum mice fed low-fat diet (LFD) served as controls. After 6 weeks, we performed complete blood counts (CBC), peripheral blood immunophenotyping, and single-cell RNA sequencing on peripheral blood mononuclear cells and Cd117+ bone marrow progenitor-enriched cells. Monocyte subsets were annotated using canonical markers, pathway activity was assessed by unbiased Hallmark gene-set enrichment analysis (GSEA), and top differential gene programs like oxidative phosphorylation (OXPHOS) were modeled as a function of monocyte maturation score and treatment group. HSC/MPP cycling was quantified by per-cell S/G2M scoring. The effect of weight regain on peripheral blood monocytes was evaluated longitudinally by comparing population switches between the stable and weight-reduced state and after 6 weeks of treatment cessation. 

Results: At equivalent weight loss, tirzepatide and CR produced distinct effects on peripheral immune phenotypes. CR caused multilineage cytopenias, with reduced hemoglobin (-31%, p=0.010), total white blood cells (-63%, p=0.001), neutrophils (-50%, p=0.048), lymphocytes (-63%, p=0.001), and T cells (-52%, p<0.0001). Tirzepatide preserved these lineages (-3% to -20%, relative to HFD, p≥0.289 for all) while selectively reducing circulating monocytes (-62%, p=0.019), particularly the Ly6Chi CCR2+ classical inflammatory subtype (-41%, p=0.007).

In HSC/MPPs, obesity increased G2M checkpoint pathway activity (HFD vs LFD, padj=0.013). In contrast, CR coordinately suppressed proliferative metabolic programs versus HFD, including MYC targets (NES -2.14, padj=3x10-7), E2F targets (NES -1.72), G2M checkpoint (NES -1.63), and OXPHOS (NES -1.74), whereas tirzepatide produced only weak, nonsignificant trends. Consistent with GSEA, the fraction of HSC/MPPs in S or G2M phases was lowest with CR (HFD 62.6%, CR 55.8%, tirzepatide 62.3%, LFD 61.4%); CR differed significantly from tirzepatide (p=0.035) and trended lower than HFD (p=0.053), while tirzepatide was identical to HFD (p=0.92).

In peripheral blood, monocytes formed a continuous classical-to-non-classical maturation trajectory, with classical monocytes enriched for NLRP3-priming genes. Glp1r and Gipr mRNAs were not detected in monocytes. OXPHOS was the dominant program distinguishing tirzepatide-treated monocytes: HFD increased OXPHOS relative to LFD, whereas tirzepatide reduced a composite electron-transport-chain score by 37% to near LFD levels. After adjustments for maturation state, OXPHOS remained lower with tirzepatide than HFD (p=0.03), but CR did not differ from HFD (p=0.72). This effect was greatest in classical monocytes (-19%, p=0.046) and was absent in marrow common monocyte progenitors. Finally, we profiled legacy effect in the Ly6Chi CCR2+ monocyte population after weight-regain linked to tirzepatide and CR cessation. We observed a significant inflammatory monocyte rebound only in the tirzepatide group (2.6% to 5.5% of PBMCs, +113%, p=0.009) whereas their levels were stable across the body weight stages in CR and the HFD and LFD controls. 

Conclusions: Weight-matched CR and tirzepatide remodel hematopoiesis through distinct mechanisms. Obesity activates an HSC/MPP G2M transcriptional program, while CR broadly suppresses progenitor proliferation and causes multilineage cytopenias. In contrast, tirzepatide preserves HSC/MPP cycling and most blood lineages while selectively and reversibly suppressing inflammatory monocytes. The absence of detectable monocyte Glp1r/Gipr mRNA and the lack of a tirzepatide-associated OXPHOS shift in marrow monocyte progenitors support an indirect systemic mechanism that reprograms circulating/peripheral monocytes rather than broadly suppressing hematopoiesis.
Nathan M. Krah, MD, PhD: No relevant conflicts of interest to declare.